Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
New pill could tame focal seizures when other drugs fail Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
New eye drug could slash injection frequency for wet AMD patients Results expected Oct 2026 (estimated) 🚀 Make-or-break
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company, so this Phase 1/2 trial of OCU400, a gene therapy for three inherited retinal diseases, is a core value driver. The trial tests safety and efficacy in 22 to 24 patients, and a positive readout could validate the therapy's broad approach across multiple mutations. For a company this size, the result of this small study carries outsized weight.
If it works: A positive safety and efficacy result could position OCU400 as a promising treatment for multiple forms of blindness, potentially attracting partners or funding. It could also support the company's path toward larger trials and eventual regulatory discussions.
If it fails: The trial could fail to show meaningful vision improvement or reveal safety problems, which would likely set the program back. Early-stage trials often fail, and a negative result for a micro-cap company could be severe, as the company has few other assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
New vaccine aims to better protect blood cancer patients from COVID-19
Vaccine OngoingThis phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category c…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: GeoVax, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 09:04 UTC
Result impactHighMicro-cap Phase 2 Readout in ~3 moA small company. This result carries real weight for it.
GeoVax, Inc. · GOVX NASDAQ Trade on eToro (ad)Why investors are watching
GeoVax is testing its vaccine GEO-CM04S1 against standard mRNA COVID-19 vaccines in 63 blood cancer patients who had stem cell transplants or cellular therapy. This is a small company, so this phase 2 readout could define whether its vaccine has a meaningful edge in a vulnerable patient group where standard vaccines may work poorly.
If it works: If GEO-CM04S1 produces a stronger immune response or better protection than mRNA vaccines in these patients, GeoVax could gain a foothold in a niche market for immunocompromised people. That result might also support further development and partnerships.
If it fails: The trial could fail to show an advantage, or the company could face delays in enrollment or data. Most phase 2 trials do not lead to approved products, so a negative or unclear result would likely hurt the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
New novavax JN.1 vaccine trial aims to protect adults 50-64 from COVID
Vaccine OngoingThis is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for …
Results expected Nov 2026 (estimated)
Phase 4 • Sponsor: Novavax • Aim: Vaccine
Last updated Jun 27, 2026 12:30 UTC
Result impactHighSmall-cap Readout in ~2 moA small company. This result carries real weight for it.
Novavax · NVAX NASDAQ Trade on eToro (ad)Why investors are watching
Novavax is testing its updated JN.1 COVID-19 vaccine in 6,500 adults aged 50 to under 65 without high-risk conditions. This Phase 4 post-marketing study matters because a positive result could support broader use of the vaccine in a large, generally healthy age group, which is important for a small company whose revenue depends on COVID vaccine sales.
If it works: A positive result could strengthen Novavax's position in the adult COVID vaccine market and support future recommendations for this age group. That could help the company maintain a steady revenue stream from its only commercial product.
If it fails: The trial could fail to show the vaccine prevents COVID better than placebo, or safety issues could emerge. Trials fail often, and a negative result would likely hurt Novavax's credibility and sales prospects for this vaccine.
AI-written from the trial record. Speculative, and not investment advice.
-
RSV booster study aims to keep seniors safe for five seasons
Vaccine OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactHighLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
5,000 volunteers tracked to see if chikungunya vaccine is safe
Vaccine OngoingThis is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
Results expected Oct 2026 (estimated)
Sponsor: Valneva Austria GmbH • Aim: Vaccine
Last updated Jul 23, 2026 00:00 UTC
Result impactHighSmall-cap Readout in ~6 wkA small company. This result carries real weight for it.
Valneva SE · VALN NASDAQ Trade on eToro (ad)Why investors are watching
Valneva SE is running a large observational safety study of its VLA1553 vaccine candidate through its Austrian subsidiary, Valneva Austria GmbH. For a small-cap vaccine maker, a safety readout on 5,000 participants carries outsized weight because safety problems can halt a program or delay regulatory review. The result will tell investors whether the vaccine's risk profile stays clean at scale.
If it works: A clean safety result could support regulatory submissions and help Valneva move the vaccine toward market. That would strengthen the company's pipeline and its position as a vaccine developer.
If it fails: A safety signal or slow enrollment could delay the program and raise questions about the vaccine's viability. Trials fail or stall often, so a negative outcome would pressure Valneva's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
New Needle-Freeze? muscle shot chickenpox vaccine tested in toddlers
Vaccine Recruiting nowThis study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Add…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout dueA large company. One readout moves the needle only so far.
-
New pneumonia vaccine VAX-31 aims to boost protection in older adults
Vaccine OngoingThe study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Results expected Mar 2027 (estimated)
Phase 3 • Sponsor: Vaxcyte, Inc. • Aim: Vaccine
Last updated Jul 02, 2026 00:00 UTC
Vaxcyte, Inc. · PCVX NASDAQ Trade on eToro (ad)Result impactHighMid-cap Phase 3, decisive Readout in ~5 moA mid-sized company with other programmes alongside this one.
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
Vaccine Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New chickenpox shot shows promise in toddler trial
Vaccine Recruiting nowThe purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 t…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~3 moA large company. One readout moves the needle only so far.
-
New chickenpox vaccine for toddlers shows promise in safety trial
Vaccine Recruiting nowThe purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have nei…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New mRNA vaccine aims to stop the stomach flu
Vaccine OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
New vaccine aims to protect kids from pneumonia – study underway
Vaccine OngoingThe purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
Vaccine OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New RSV vaccine aims to shield adults from severe respiratory infection
Vaccine Recruiting nowThe purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Aug 16, 2026 00:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New vaccine aims to shield sickle cell kids from deadly infections
Vaccine Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
Vaccine OngoingThe purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate …
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:03 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
Vaccine OngoingThe main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adole…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
New chickenpox vaccine shows promise in toddler trial
Vaccine Recruiting nowThe purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax.…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~3 moA large company. One readout moves the needle only so far.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
New mRNA flu vaccine trial aims to stop future pandemics
Vaccine OngoingThe purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemag…
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 moA large company. One readout moves the needle only so far.
-
Two-Drug malaria punch targets faster cure in kids
Cure Recruiting nowThis was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Novartis AG · NVS NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~5 moA large company. One readout moves the needle only so far.
-
BioNTech launches first human test of mRNA herpes vaccine
Vaccine OngoingThis exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety ev…
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Result impactLowLarge company Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
Vaccine OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:34 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
Vaccine OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactLowLarge company Readout in ~3 wkA large company. One readout moves the needle only so far.
-
New RSV vaccine trial offers hope for transplant patients
Vaccine OngoingThis study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Results expected Jan 2027 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Follow-on study Readout in ~4 moA follow-on study — an extension, safety or dosing run, not the deciding result.
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
Vaccine OngoingThe main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 p…
Results expected Mar 2027 (estimated)
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactLowLarge company Phase 2 Readout in ~6 moA large company. One readout moves the needle only so far.
-
One shot to rule them all? new combo meningitis vaccine tested in teens
Vaccine OngoingThe purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Results expected Mar 2027 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:06 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Phase 2 Readout in ~6 moA large company. One readout moves the needle only so far.
-
New vaccine trial aims to shield korean babies from deadly meningitis
Vaccine OngoingThe purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republic of Korea according to a 2-dose primary schedule and 1 booster dose.
Results expected Sep 2026 (estimated)
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:04 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Readout dueA large company. One readout moves the needle only so far.
-
Massive study checks if PCV20 vaccine stops pneumonia in At-Risk adults
Vaccine OngoingThe purpose of this study is to learn how well PCV20 stops adults from getting community-acquired pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be…
Results expected Sep 2026 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Aug 27, 2026 00:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Double defense: new mRNA vaccine targets two lung viruses in seniors
Vaccine OngoingThe aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevent…
Results expected Jan 2027 (estimated)
Phase 1/2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 08:03 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Result impactLowMega-cap Phase 2 Readout in ~4 moA large company. One readout moves the needle only so far.
-
Massive study of 22 million seniors tests pneumonia Vaccine's Real-World power
Vaccine OngoingThe purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia (a bacterial lung disease caused by the germ Strepto…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~6 wkA large company. One readout moves the needle only so far.
-
One shot for two viruses? new combo vaccine enters early human testing
Vaccine Recruiting nowThis early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVI…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jul 02, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~2 moA large company. One readout moves the needle only so far.
-
New vaccine safety check for infants: PREVENAR 20 under Real-World scrutiny
Vaccine OngoingThe purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan. This study is seeking for infants aged between two months to six months who are vaccinated with PREVENAR 20 for the first tim…
Results expected Dec 2026 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
New pneumonia vaccine candidate enters early human testing
Vaccine OngoingThis study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:38 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
New HPV vaccine aims to block more cancer types in early trial
Vaccine OngoingResearchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For som…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Result impactLowMega-cap Readout in ~2 moA large company. One readout moves the needle only so far.
-
New mRNA vaccines aim to outsmart evolving COVID variants
Vaccine Recruiting nowThe purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Results expected Dec 2026 (estimated)
Phase 4 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:01 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
New pneumonia vaccine booster for toddlers enters safety trial
Vaccine Recruiting nowThe main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 wil…
Results expected Feb 2027 (estimated)
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~5 moA large company. One readout moves the needle only so far.
-
Korean study monitors prevenar 20 vaccine safety
Vaccine Recruiting nowThe purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea. This study is seeking for participants who a…
Results expected Mar 2027 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~5 moA large company. One readout moves the needle only so far.
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.